AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 102 min read$PRCT

PROCEPT BioRobotics Corp (PRCT): Submission of Matters to a Vote of Security Holders

PROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. prct-20260609 0001588978 false 0001588978 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
SEC EDGAR 8-K
Published Jun 10, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$PRCT
Neutral
medium confidence
Mentioned
$PRCT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PRCTNeutralLow
01

Why it matters

Confirms that all director nominees were elected and that PricewaterhouseCoopers LLP was ratified as independent auditor for the year ending Dec. 31, 2026; also reports the non-binding advisory vote on executive compensation.

02

Market read

Primarily governance housekeeping; useful for completeness but not a standalone fundamental catalyst.

03

What to watch

Traders may instead focus on upcoming clinical/financial catalysts; this 8-K mainly updates corporate governance status rather than business performance.

Relevance 6/10Novelty 2/10Timing: after-hours/filing day (June 10, 2026)

Background

The article is an SEC 8-K (Item 5.07) reporting matters submitted to a vote of security holders at PROCEPT BioRobotics’ June 9, 2026 annual meeting.

Company-level read

Ticker impact

$PRCTNeutralMedium confidence
Context

PROCEPT BioRobotics (PRCT) disclosed June 9, 2026 annual meeting voting results, including director elections and auditor/compensation proposals.

Expected impact

Likely limited near-term impact; any reaction would be second-order unless investors were expecting a contested outcome.

Evidence & confidence

The filing is an 8-K Item 5.07 with vote tallies; it does not introduce new financial guidance, regulatory decisions, or material corporate actions beyond governance confirmations.

Market effects

Sector

No direct read-across to sector fundamentals; governance vote results are company-specific.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If there had been a close or contested vote, governance uncertainty could matter; however, the filing provides results without signaling controversy or change in strategy.

Key entities

  • issuer
    PROCEPT BioRobotics Corporation

    Nasdaq-listed company filing the 8-K with annual meeting voting results.

  • auditor
    PricewaterhouseCoopers LLP

    Ratified as independent registered public accounting firm for 2026 per Proposal 2.

Read at source← All news

Related articles

AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min
AUG 8
$BPMedAI 8/10

BP Chair Who Sped Up Company’s Turnaround Fired Over Conduct

BP PLC fired Chairman Albert Manifold months after he took the role, citing serious concerns about governance standards, oversight, and conduct, according to BP’s board. BP shares fell about 9.3% after the news, with the stock at 529 pence in London. The move adds to leadership churn as BP seeks a turnaround under CEO Meg O’Neill.

energynow.com4 min
AUG 8
$000660.KSMed

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.

businesstimes.com.sg3 min